ScreenerHero

MRKRMarker Therapeutics, Inc.

NAS · US · Healthcare · Biotechnology · markertherapeutics.com
1.390USD+7.75%Mkt Cap: 23.18M $P/E: —

Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, develops and commercializes T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications in the United Stat…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$138.82BUSDP/E 31.9
REGN
Regeneron Pharmaceuticals, Inc.
$85.87BUSDP/E 20.5
ARGX
ARGENX SE
$61.34BUSDP/E 39.8
ARGX
argenx SE
$65.05BUSDP/E 39.6
MRNA
Moderna, Inc.
$57.94BUSD
UCB
UCB SA
$45.95BUSDP/E 19.6
RVMD
Revolution Medicines, Inc.
$44.89BUSD
ONC
BeOne Medicines AG
$42.36BUSDP/E 67.2
RPRX
Royalty Pharma Plc Class A
$35.43BUSDP/E 32.6
ALNY
Alnylam Pharmaceuticals, Inc.
$31.61BUSDP/E 41.2
BNTX
BioNTech SE
$29.28BUSD
INSM
Insmed Incorporated
$27.47BUSD
ROIV
Roivant Sciences Ltd. Common Shares
$26.22BUSD
INCY
Incyte Corporation
$25.91BUSDP/E 16.2
GMAB
Genmab A/S
$20.86BUSDP/E 26.3
GMAB
Genmab A/S
$19.26BUSDP/E 26.6
ASND
Ascendis Pharma A/S
$16.61BUSDP/E 19.6
JAZZ
Jazz Pharmaceuticals plc
$16.51BUSDP/E 17.4
BBIO
BridgeBio Pharma, Inc.
$15.93BUSD
EXEL
Exelixis, Inc.
$13.40BUSDP/E 17.0

Key Statistics

Company
Market Cap23.18M $
Enterprise Value9.01M $
Revenue (TTM)2.69M $
Gross Profit-1.80M $
Net Income (TTM)-12.16M $
Revenue/Share0.1440 USD
Last Price1.390 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees5
CountryUS
SectorHealthcare
IndustryBiotechnology
ISINUS57055L2060
Valuation
P/E (Trailing)—
P/E (Forward)-2.30
PEG—
EV/EBITDA—
EV/Revenue3.36
P/S7.57
P/B1.68
EPS (TTM)-0.36
EPS (Forward)-0.53
52W Range
0.810035% of range2.460
52W High2.460 USD
52W Low0.8100 USD
Profitability
Gross Margin-67.07%
Oper. Margin-385.95%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-72.42%
ROA-63.78%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-12.01M $
CapEx (TTM)—
FCF Margin-265.85%
FCF Yield-30.81%
Net Debt-11.33M $
Net Debt/EBITDA—
Balance Sheet
Debt/Equity—
Current Ratio6.03
Quick Ratio5.35
Book Value/Sh0.7280 USD
Cash/Share0.6800 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay DateSep 16, 2016
Splits
Last Split1:10
Split DateJan 27, 2023
Analyst Consensus
Rating1.0 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)7.867 USD
Upside (mean)+465.9%
Target Range5.600 USD – 10.00 USD
$5.600+465.9% to mean$10.00
# Analysts3
Ownership
Shares Out.16.67M
Float13.74M
Insiders5.49%
Institutions23.80%
Short Interest
Short Ratio2.6d
Short % Float1.14%
Short % Out.0.93%
Shares Short154.35K
Short (prev mo.)116.65K
Technical
SMA 501.306 (+6.5%)
SMA 2001.412 (-1.6%)
Beta—
S&P 52W Chg18.16%
Avg Vol (30d)52.85K
Avg Vol (10d)69.39K
Technical Indicators
RSI (14)62.8
MACD-0.0217
MACD Signal-0.0514
MACD Hist.+0.0297
BB Upper1.327 USD
BB Middle1.180 USD
BB Lower1.033 USD
BB Width24.98%
ATR (14)0.0936 USD
Vol Ratio (20d)1.77x